AKAP4 and non-small cell lung carcinoma: Similarly to our previous study of SP17 in non-small cell lung cancer [6] and AKAP-4 in prostate cancer [17], we at first evaluated SP17 immunogenicity by detecting serum anti-SP17 autoantibodies in HNSCC patients.